How to Quit Nicotine Pouches

Why are nicotine pouches so hard to quit?

Nicotine pouches — sold under brands like Zyn, On!, and Velo — are small tobacco-free pouches placed between the gum and lip. Nicotine is absorbed through the oral mucosa, delivering a pharmacokinetic profile broadly similar to a nicotine lozenge at standard doses 1Ref 1Azzopardi D, Ebajemito J, McEwan M, et al. (2022).A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products.Nicotine bioavailability of pouches is similar to a nicotine lozenge at standard doses. At higher strengths (8 mg and above), plasma nicotine levels can approach or exceed those from cigarettes 2Ref 2Mallock-Ohnesorg N, Rabenstein A, Stoll Y, et al. (2024).Small pouches, but high nicotine doses — nicotine delivery and acute effects after use of tobacco-free nicotine pouches.High-dose nicotine pouches (30 mg) can deliver higher plasma nicotine than cigarettes.

Because the pouches are smoke-free, odorless, and available in fruit and mint flavors, they are easy to use continuously throughout the day — at a desk, in a car, in settings where smoking or vaping would draw attention. This convenience enables high daily use and, in turn, significant nicotine dependence 3Ref 3Dowd AN, Thrul J, Czaplicki L, Kennedy RD, Moran MB, Spindle TR (2024).A Cross-Sectional Survey on Oral Nicotine Pouches: Characterizing Use-Motives, Topography, Dependence Levels, and Adverse Events.Nicotine pouch users demonstrate significant dependence; 48% report mouth lesions as adverse event.

A 2024 cross-sectional survey of 118 adult pouch users found that more than a third met criteria for substantial nicotine dependence, and 48% reported mouth lesions as an adverse event from use 3Ref 3Dowd AN, Thrul J, Czaplicki L, Kennedy RD, Moran MB, Spindle TR (2024).A Cross-Sectional Survey on Oral Nicotine Pouches: Characterizing Use-Motives, Topography, Dependence Levels, and Adverse Events.Nicotine pouch users demonstrate significant dependence; 48% report mouth lesions as adverse event. Withdrawal from pouches follows the same pattern as withdrawal from any nicotine product: irritability, cravings, difficulty concentrating, and restlessness — driven by the brain's adaptation to regular nicotine stimulation.

Who is using nicotine pouches?

Use of nicotine pouches has grown rapidly in the United States, particularly among young people. CDC surveillance data from 2024 found that 1.8% of middle and high school students reported current pouch use, with Zyn accounting for nearly 69% of use among student users 4Ref 4Park-Lee E, Jamal A, Cowan H, et al. (2024).Notes from the Field: E-Cigarette and Nicotine Pouch Use Among Middle and High School Students — United States, 2024.1.8% of US middle and high school students reported current nicotine pouch use in 2024; Zyn accounted for 68.7% of brand use. A cross-sectional analysis of Monitoring the Future survey data found that lifetime pouch use among 10th and 12th graders nearly doubled — from 3.0% in 2023 to 5.4% in 2024 — while e-cigarette use declined over the same period, suggesting some substitution effect 5Ref 5Han DH, Harlow AF, Miech RA, et al. (2025).Nicotine Pouch and E-Cigarette Use and Co-Use Among US Youths in 2023 and 2024.Lifetime nicotine pouch use among 10th/12th graders nearly doubled from 3.0% to 5.4% between 2023 and 2024.

Nicotine's effects on the developing brain are a specific concern in younger users. Nicotine exposure during adolescence has been associated with changes in cortical thickness and subcortical brain volumes involved in attention, memory, and impulse control — effects that can persist into adulthood 6Ref 6Ye D, Rahman I (2023).Emerging Oral Nicotine Products and Periodontal Diseases.Nicotine exposure during adolescent brain development; nicotine pouches appeal to youth; nicotine periodontal effects.

Among adults, pouches are often adopted by people who have switched from cigarettes, snus, or vaping, or who use them alongside other nicotine products ("dual use"). Dual or triple use increases total daily nicotine exposure and can complicate cessation planning.

What are the options for quitting?

The clinical evidence base for quitting nicotine pouches specifically is limited — clinical trials for pouches are few and small 7Ref 7Heshmati R, et al. (2025).Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials.Clinical trial evidence specific to nicotine pouches for cessation is limited; none of seven small trials showed statistically significant increase in cessation vs control. However, nicotine dependence is the underlying problem regardless of delivery form, and the evidence base for treating nicotine dependence in general is robust.

Gradual reduction. Stepping down to lower-strength pouches over several weeks before stopping completely reduces the abruptness of withdrawal. Many users find this more manageable than stopping abruptly, though the quit timeline is longer.

Switching to a different form of NRT. Replacing pouches with a nicotine patch, lozenge, or gum severs the behavioral ritual while maintaining nicotine delivery during a transition period. A Cochrane review of 78 trials found that any form of NRT roughly doubles the likelihood of successfully quitting compared with no pharmacologic support 8Ref 8Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T (2018).Nicotine Replacement Therapy versus Control for Smoking Cessation.Any form of NRT roughly doubles the likelihood of successfully quitting compared with no pharmacologic support. The NRT form is chosen based on preference and use pattern — a patch provides background nicotine; gum or lozenge addresses acute cravings.

Cold turkey. Stopping abruptly works for a meaningful minority and means a shorter but more intense withdrawal period. It requires coping strategies for the acute phase (typically the first three to five days).

Prescription medications. Varenicline (Chantix/Champix) is a partial nicotinic receptor agonist that reduces cravings and blunts the rewarding effects of nicotine. A 2023 Cochrane review found varenicline significantly more effective than placebo and more effective than bupropion for smoking cessation 9Ref 9Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. (2023).Nicotine Receptor Partial Agonists for Smoking Cessation.Varenicline is significantly more effective than placebo and more effective than bupropion for smoking cessation. The large EAGLES trial established that varenicline and bupropion do not increase neuropsychiatric adverse events compared to placebo in smokers with and without psychiatric conditions 10Ref 10Anthenelli RM, Benowitz NL, West R, et al. (2016).Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers with and without Psychiatric Disorders (EAGLES): A Double-Blind, Randomised, Placebo-Controlled Clinical Trial.Varenicline and bupropion do not increase neuropsychiatric adverse events compared to placebo in smokers with or without psychiatric conditions. These medications target nicotine dependence — not a specific product — and a clinician can discuss whether they are appropriate for your situation.

Combination approaches. Combining NRT with behavioral counseling or a quit program consistently outperforms either alone. The US Preventive Services Task Force recommends that clinicians offer cessation interventions to all adults who use tobacco, including combined behavioral and pharmacologic support 11Ref 11US Preventive Services Task Force (2021).Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement.USPSTF recommends clinicians offer cessation interventions to all adults who use tobacco, including combined behavioral and pharmacologic support.

What does withdrawal actually feel like — and how long does it last?

Expect cravings, irritability, difficulty concentrating, and restlessness. Some people notice increased appetite or disrupted sleep. The intensity of withdrawal depends on how much nicotine you were taking in daily — someone using six high-strength (8–16 mg) pouches a day will experience more intense withdrawal than someone using two low-strength (3 mg) pouches.

The acute physical symptoms typically ease within one to two weeks. Situational cravings — triggered by specific contexts like driving, finishing a meal, or stress — can persist for weeks to months. These are conditioned cues, not signs that the dependence is permanent. Planning a substitute behavior for each identified trigger (a glass of water, a brief walk, sugar-free gum) is a practical behavioral strategy.

For people with underlying anxiety or depression, nicotine withdrawal may surface or worsen those conditions temporarily. This is a reason to have clinician support during the quit attempt — not a reason to avoid quitting.

What about oral health — should you see a dentist?

Nicotine pouches are placed in contact with the gingival and buccal mucosa for extended periods. A 2024 systematic review of available clinical evidence found that mucosal changes at the site of placement were the most consistently reported finding among regular users, along with dry mouth and localized soreness 12Ref 12Rungraungrayabkul D, Gaewkhiew P, Vichayanrat T, Shrestha B, Buajeeb W (2024).What is the impact of nicotine pouches on oral health: a systematic review.Mucosal changes at pouch placement site, dry mouth, and localized soreness are the most consistently reported oral health findings among nicotine pouch users. A peer-reviewed dental review notes that localized gingival recession — similar in mechanism to that seen with snus — has been observed, and that long-term risks are not yet well characterized because these products have only been widely available since the late 2010s 13Ref 13Jackson JM, Weke A, Holliday R (2023).Nicotine pouches: a review for the dental team.Long-term oral health risks of nicotine pouches are not yet well characterized; localized gingival recession has been observed; pouches contain no tobacco leaf. Critically, unlike traditional smokeless tobacco, pouches do not contain tobacco leaf and its associated carcinogenic tobacco-specific nitrosamines — though periodontal effects of nicotine itself, separate from tobacco, remain a concern 14Ref 14American College of Obstetricians and Gynecologists (2020).Tobacco and Nicotine Cessation During Pregnancy: ACOG Committee Opinion, Number 807.ACOG recommends discussion of cessation for all pregnant patients using any tobacco or nicotine product; NRT may be considered when behavioral approaches are insufficient.

If you have been using pouches regularly for a significant period, a dental evaluation is worthwhile, particularly for changes at the placement site. Tell your dentist how long you have been using them and where you typically place them.

When should you involve a clinician?

If previous quit attempts have failed, if withdrawal is severe enough to affect your daily functioning, or if you want access to prescription-strength support, a primary care clinician is the right starting point. Cessation medications are indicated for nicotine dependence regardless of the delivery form — they are not cigarette-specific.

Things to bring to the appointment: the brand and nicotine strength of pouches you use, how many per day, how long you have been using them, any previous quit attempts and what happened, your current medications, and any oral symptoms.

For anyone using nicotine pouches during pregnancy: ACOG recommends that clinicians discuss cessation with all pregnant patients who use any tobacco or nicotine product, and that NRT may be considered when behavioral approaches have not been sufficient ^[?].